The pharmacokinetics of pioglitazone in patients with impaired renal function.
about
Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrationsManagement of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic controlDiabetic kidney disease: a report from an ADA Consensus ConferenceActivation of PPARγ in myeloid cells promotes lung cancer progression and metastasisUpdate on the treatment of type 2 diabetes mellitusOverview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Diabetes treatment in patients with renal disease: Is the landscape clear enough?Investigation of the antibacterial activity of pioglitazone.Management of Hyperglycemia in Diabetic Kidney Disease.Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary careToxicological evaluation of subchronic use of pioglitazone in mice.Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.Pioglitazone: side effect and safety profile.Thiazolidinedione safety.Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.Examining the safety of PPAR agonists - current trends and future prospects.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Noninsulin glucose-lowering agents for the treatment of patients on dialysis.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Anti-diabetes therapy: safety considerations for patients with impaired kidney function.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions.Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.Optimal study design for pioglitazone in septic pediatric patients.Pharmacokinetics of pioglitazone in lean and obese cats.Pharmacokinetics of pioglitazone after multiple oral dose administration in horses.Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.Comparative in vitro-in vivo correlation analysis with pioglitazone tabletsPioglitazone, a PPAR-γ Activator, Stimulates BK but Suppresses IK in Hippocampal Neurons
P2860
Q24642826-06AD1186-9D41-4698-9C5D-D5C17460FE23Q26766259-E27EEADE-0F22-450D-9E0E-30BFE9D0F861Q27012546-3FB10634-56A0-4BE9-A101-B6A733CD080BQ27311601-E2FD876B-257B-4462-B190-E3550A450242Q28073342-847C8472-6C50-4A54-A9B4-F5500678A170Q31025919-06404686-DAE3-41EC-8BF8-9D168AE2B6CBQ34068430-9EA480DF-7A4A-498C-ACAB-E2F94E9C4ED0Q35533449-315856D7-8C47-4470-8FDD-BD61F3225DF6Q35953856-CCDB40E9-C6D4-4CB2-ABBE-D744482A1198Q36753481-C5AE4047-B2DA-4177-8635-82AAF396E693Q37231096-2A0F1862-82DC-4A9E-9402-CE3CD58BA613Q37265286-9BF2E297-7807-48A7-BC4A-BF1777BEC3CAQ37428857-95C7E051-B592-4EDE-A0DD-4EB35E0574B3Q37696508-016EC1A4-707C-4925-920A-3380BD9E0798Q38012205-601A9433-1EEF-40D2-8894-68F7F9CF4CC3Q38036778-2CDE44C6-CE1B-4E40-9944-F76D2817599EQ38058381-D84237D0-5055-421F-ADF1-713E607AA32EQ38059889-9A64621B-67A8-4E35-8320-E45C38610585Q38077451-87673314-CEF3-44E4-B635-174B895D00F5Q38086611-97216F4A-1463-4739-B10A-64DC9421CBEDQ38219489-046417E4-5F08-4AC1-803F-D095F3B7F2CAQ38455771-8B0C56AB-FA55-435C-ACC9-9D20BF745986Q38541323-7CC5836A-067A-4C9C-B3AB-3906B972D570Q38688345-44BC3EBE-20BC-4F9B-8767-F87E00FADF4DQ39689968-61C12D9F-DB96-4F89-9246-76787E729846Q40873693-766B8CC5-EF16-4B7E-9B65-BDBD64ED2695Q41585973-DF78325F-C496-4AAC-9227-5DD3302D729AQ44080987-1D0F3446-2F6A-4733-9446-64B03A67B085Q44965022-A867F1A5-2944-4327-B05E-B27DF6D3A1C8Q45111558-BFC3AD7A-F508-4070-9DF7-9A5747A4B562Q46207930-F730CEF8-3720-4022-9427-32C11E09F064Q46241434-CDA48089-47AD-4836-86AD-A4B51B8362CBQ53645972-E6E86631-3206-48E0-B9B2-41C04B30FD01Q57932324-4CE2FC4B-7E72-4288-B010-72F25449BAEAQ58694208-40427429-D5D5-4592-BCB8-E0E5518CC3D6
P2860
The pharmacokinetics of pioglitazone in patients with impaired renal function.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@ast
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@en
type
label
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@ast
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@en
prefLabel
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@ast
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@en
P2093
P2860
P1476
The pharmacokinetics of pioglitazone in patients with impaired renal function.
@en
P2093
David Eckland
Hans-Hellmut Neumayer
Klemens Budde
Lutz Fritsche
Tomasz Stompôr
Wladyslaw Sulowicz
P2860
P304
P356
10.1046/J.1365-2125.2003.01785.X
P407
P577
2003-04-01T00:00:00Z